August 3, 2020

Merck plans large trials of antiviral COVID-19 drug in September – Reuters

image

FILE PHOTO: The Merck logo is seen on a sign at the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

NEW YORK (Reuters) – Drugmaker Merck & Co said on Friday it plans to start two large pivotal trials in September on the experimental oral antiviral COVID-19 drug it is developing with privately held Ridgeback Biotherapeutics.

Speaking on a conference call with investors, Merck’s research chief Roger Perlmutter said the company has secured manufacturing capability to make “many millions of doses” of the drug before year end. The experimental drug is currently in phase 2 trials.

Reporting by Michael Erman; Editing by Chris Reese

This post originally appeared on and written by:
Reuters Editorial
Reuters

Share
Source: